Agree, a very solid conference call which should give the longer term investor confidence.
The rigorous testing these large organisations are doing alongside Bio-Gene is worth a significant amount, the data and any created Intellectual property can further open up additional opportunities.
No company has ceased internal testing, and additional partners lining up that is an excellent sign which places Bio-Gene in a strong negotiating position. No exclusivity has been granted yet.
This reminds me of MYQ which was a 10 bagger for me. It similarly was under IPO price for over 2 years then rocketed from 4c-$1.50 in the space of 8 weeks on the back of a few partnerships. It's now at 28c.
Bio-Gene may take a while longer, but it's time in the sun will certainly come.
